[1] A. Bergquist, E. von Seth, Epidemiology of cholangiocarcinoma. Best practice & research. Clinical gastroenterology 29 (2015) 221-232.
[2] F. Cauchy, M. Mebarki, B. Leporq, S. Laouirem, M. Albuquerque, S. Lambert, P. Bourgoin, O. Soubrane, B.E. Van Beers, S. Faivre, P. Bedossa, V. Paradis, Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. Clinical science 131 (2017) 27-36.
[3] X. Hu, Z. Huang, Z. Liao, C. He, X. Fang, Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients. International journal of clinical and experimental pathology 7 (2014) 6716-6724.
[4] A. Hulikova, N. Aveyard, A.L. Harris, R.D. Vaughan-Jones, P. Swietach, Intracellular carbonic anhydrase activity sensitizes cancer cell pH signaling to dynamic changes in CO2 partial pressure. The Journal of biological chemistry 289 (2014) 25418-25430.
[5] K. Kalavska, Z. Cierna, M. Chovanec, M. Takacova, D. Svetlovska, V. Miskovska, J. Obertova, P. Palacka, J. Rajec, Z. Sycova-Mila, K. Machalekova, K. Kajo, S. Spanik, J. Mardiak, P. Babal, S. Pastorekova, M. Mego, Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors. Oncology letters 13 (2017) 2177-2185.
[6] Y. Kato, S. Ozawa, C. Miyamoto, Y. Maehata, A. Suzuki, T. Maeda, Y. Baba, Acidic extracellular microenvironment and cancer. Cancer cell international 13 (2013) 89.
[7] W.H. Kuo, W.L. Chiang, S.F. Yang, K.T. Yeh, C.M. Yeh, Y.S. Hsieh, S.C. Chu, The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life sciences 73 (2003) 2211-2223.
[8] Y. Luo, T.S. Mok, X. Lin, W. Zhang, Y. Cui, J. Guo, X. Chen, T. Zhang, T. Wang, SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma. Scientific reports 7 (2017) 41191.
[9] N.M. Maruthur, E. Tseng, S. Hutfless, L.M. Wilson, C. Suarez-Cuervo, Z. Berger, Y. Chu, E. Iyoha, J.B. Segal, S. Bolen, Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Annals of internal medicine 164 (2016) 740-751.
[10] I. Nishimori, S. Onishi, Carbonic anhydrase isozymes in the human pancreas. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 33 (2001) 68-74.
[11] N. Noma, G. Fujii, S. Miyamoto, M. Komiya, R. Nakanishi, M. Shimura, S.I. Tanuma, M. Mutoh, Impact of Acetazolamide, a Carbonic Anhydrase Inhibitor, on the Development of Intestinal Polyps in Min Mice. International journal of molecular sciences 18 (2017).
[12] K. Nordfors, J. Haapasalo, M. Korja, A. Niemela, J. Laine, A.K. Parkkila, S. Pastorekova, J. Pastorek, A. Waheed, W.S. Sly, S. Parkkila, H. Haapasalo, The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC cancer 10 (2010) 148.
[13] J. Pastorek, S. Pastorekova, Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Seminars in cancer biology 31 (2015) 52-64.
[14] S. Pastorekova, M. Zatovicova, J. Pastorek, Cancer-associated carbonic anhydrases and their inhibition. Current pharmaceutical design 14 (2008) 685-698.
[15] R.R. Plentz, N.P. Malek, Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best practice & research. Clinical gastroenterology 29 (2015) 245-252.
[16] Y. Shaib, H.B. El-Serag, The epidemiology of cholangiocarcinoma. Seminars in liver disease 24 (2004) 115-125.
[17] H. Tachibana, M. Gi, M. Kato, S. Yamano, M. Fujioka, A. Kakehashi, Y. Hirayama, Y. Koyama, S. Tamada, T. Nakatani, H. Wanibuchi, Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers. Cancer science 108 (2017) 331-337.
[18] S.X. Trinh, H.T. Nguyen, K. Saimuang, V. Prachayasittikul, W. Chan On, Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells. Asian Pacific journal of cancer prevention : APJCP 18 (2017) 473-477.
[19] K. Vaeteewoottacharn, R. Kariya, P. Dana, S. Fujikawa, K. Matsuda, K. Ohkuma, E. Kudo, R. Kraiklang, C. Wongkham, S. Wongkham, S. Okada, Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 37 (2016) 9023-9035.
[20] P. Viikila, A.J. Kivela, H. Mustonen, S. Koskensalo, A. Waheed, W.S. Sly, J. Pastorek, S. Pastorekova, S. Parkkila, C. Haglund, Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas. World journal of gastroenterology : WJG 22 (2016) 8168-8177.
[21] C.N. Yeh, A. Maitra, K.F. Lee, Y.Y. Jan, M.F. Chen, Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25 (2004) 631-636.
[22] T. Yoneda, M. Hiasa, Y. Nagata, T. Okui, F. White, Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochimica et biophysica acta 1848 (2015) 2677-2684.
[23] G. Yu, W. Fang, T. Xia, Y. Chen, Y. Gao, X. Jiao, S. Huang, J. Wang, Z. Li, K. Xie, Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget 6 (2015) 12748-12762.
[24] G. Yu, W. Yu, G. Jin, D. Xu, Y. Chen, T. Xia, A. Yu, W. Fang, X. Zhang, Z. Li, K. Xie, PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Molecular cancer 14 (2015) 193.